2019 American Transplant Congress
Discovery and Validation of an Early Post-Transplant Biomarker Model Predictive of Chronic Kidney Disease in Liver Transplant Recipients
*Purpose: A significant proportion of patients develop chronic kidney disease after liver transplantation (LT). We aimed to develop clinical/protein models to predict future GFR deterioration…2019 American Transplant Congress
Renal Failure as a Complication of Vascularized Composite Allotransplantation
*Purpose: Vascularized composite allotransplantation (VCA) has demonstrated impressive outcomes in areas of extremity (UETx), face (FTx), genitourinary, and abdominal wall transplantation with up to twenty…2019 American Transplant Congress
Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population
University of Illinois at Chicago, Chicago, IL
*Purpose: Conversion to belatacept as maintenance immunosuppression has gained traction to prevent calcineurin inhibitor (CNI) induced toxicities in renal transplant (RTx) recipients. However, limited knowledge…2019 American Transplant Congress
Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation
Emory University School of Medicine, Atlanta, GA
*Purpose: A majority of kidney transplant recipients receive calcineurin inhibitor (CNI)-based immunosuppression. However, some do not tolerate CNIs and require other immunosuppressive strategies. Until recently,…2019 American Transplant Congress
A Retrospective Observational Analysis of Tacrolimus Metabolism Rate: No Evidence for Impact on Renal Function
*Purpose: A previous publication found that fast metabolisers of tacrolimus had inferior renal function compared to slow metabolisers in a Caucasian population (Thölking et al.,…2019 American Transplant Congress
Monitoring And Management Of Proteinuria Is Often Ignored In Patients Receiving mTOR Therapy Following Orthotopic Liver Transplantation
*Purpose: Use of mTOR inhibitors, such as Everolimus (EVL), in liver transplant (LT) patients continues to rise as the side effect profile becomes more evident.…2019 American Transplant Congress
Renal Safety Of Entecavir And Tenofovir With Hepatitis B Immunoglobulin In Liver Transplant Patients
*Purpose: Combination of potent nucleos(t)ide analougues (NAs) and hepatitis B immunoglobulin is recommended after liver transplantation for the prevention of hepatitis B virus (HBV) recurrence.…2019 American Transplant Congress
Eupatilin Ameliorates Tacrolimus Induced Nephrotoxicity via Inhibiting Apoptosis
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…2019 American Transplant Congress
Low Incidence of Acute Renal Failure with Minimal Prophylaxis after Iodinated-Contrast TC in Ambulatory Renal Transplant Patients
*Purpose: Kidney transplant patients are at risk of contrast-induced nephropathy. CT scan with contrast is a very common imaging test. Our objective is to study…2019 American Transplant Congress
Early Everolimus Conversion For Renal Protection In Liver Transplantation: The Sooner The Better?
Henry Ford Health System, Detroit, MI
*Purpose: Calcineurin inhibitors (CNI) are the mainstay of immunosuppressive therapy in transplantation; however, a major side effect limiting CNI use is nephrotoxicity. Mammalian target of…
American Transplant Congress abstracts